The emergence of various novel therapies over the last decade has changed the therapeutic
landscape for multiple myeloma. While the clinical outcomes have improved significantly …

The interaction of the host immune system with tumor cells in the tissue microenvironment is
essential in understanding tumor immunity and development of successful cancer …

Cancer immunotherapy modulates immune cells to induce antitumor immune responses.
Tumors employ immune checkpoints to evade immune cell attacks. Immune checkpoint …

Traditional cancer treatments use nonspecific drugs and monoclonal antibodies to target
tumor cells. Chimeric antigen receptor (CAR)-T cell therapy, however, leverages the immune …

Pancreatic tumors are highly desmoplastic and immunosuppressive. Delivery and
distribution of drugs within pancreatic tumors are compromised due to intrinsic physical and …

Harnessing the immune system to eradicate malignant cells is becoming a most powerful
new approach to cancer therapy. FDA approval of the immunotherapy-based drugs …

The adaptive immune system plays a pivotal role in the host's ability to mount an effective,
antigen‐specific immune response against tumors. CD8+ tumor‐infiltrating lymphocytes …

Chimeric antigen receptor (CAR)-modified T cell therapy has the potential to improve the
overall survival of patients with malignancies by enhancing the effectiveness of CAR T cells …

Nanomaterial-based tumor photothermal therapy (PTT) has attracted increasing attention
and been a promising method for cancer treatment because of its low level of adverse …

While active immunization elicits a lasting immune response by the body, passive
immunotherapy transiently equips the body with exogenously generated immunological …